This fact sheet is for men who have been diagnosed with locally advanced prostate cancer - cancer that's spread to the area just outside the prostate gland. It explains what locally advanced prostate cancer is, what your test results mean, and the treatment options available.


  • Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme: PSA testing in asymptomatic men. Evidence document. NHS Cancer Screen Programme. 2010
  • Berney DM. The case for modifying the Gleason grading system. BJU Int. 2007;100(4):725–6.
  • Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27.
  • Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012 Dec 8;380(9858):2018–27.
  • Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12.
  • Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, Committee IG, others. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
  • European Association of Urology. Guidelines on Prostate Cancer. 2014.
  • Hegarty J, Walsh E, Harry Comber, Tony Fitzgerald, Kazer MW. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010;
  • Hoffman KE, Nguyen PL, Chen M-H, Chen RC, Choueiri TK, Hu JC, et al. Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. J Urol. 2011 Jan;185(1):116–20.
  • Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.
  • McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology. 2010;254(1):31.
  • MDT Prostate Cancer Guidance (BUG, BAUS). 2013.
  • Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:CD007566.
  • National Institute for Health and Clinical Excellence. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. 2006;
  • NICE. Prostate Cancer: diagnosis and treatment. NICE full guideline. 2014.
  • Payne, H. Management of locally advanced prostate cancer.pdf. Asian J Androl. 2009;11:81–7.
  • Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, et al. Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem. 2001;38(3):188–216.
  • Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet. 2012;378(9809):2104–11.
  • Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301–8.

About this publication  

Updated: August 2014 | Due for Review: July 2016

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication